文献速递肾小球疾病

异常蛋白血症与肾小球疾病

Dysproteinemias and Glomerular Disease.
PubMed 文献 · Clin J Am Soc Nephrol · 2017-11-07

异常蛋白血症由B细胞克隆扩增过度产生免疫球蛋白所致,单克隆蛋白可损伤肾小球、小管和血管。肾小球损伤主要通过沉积机制,也可通过补体激活、细胞因子/生长因子或沉淀机制。具有肾毒性的克隆不满足恶性肿瘤标准时称为具有肾脏意义的单克隆丙种球蛋白病,需大幅降低单克隆蛋白以保护肾功能,克隆导向治疗如利妥昔单抗和硼替佐米较非单克隆蛋白相关肾病的免疫抑制方案更有效。

要点

  • 单克隆蛋白可损伤肾脏所有区域,肾小球主要机制为沉积。
  • 肾毒性克隆不限于恶性状态,MGRS需重视。
  • 克隆导向治疗(利妥昔单抗、硼替佐米)优于传统免疫抑制。

核心结论

  • 肾毒性单克隆蛋白可由任何B细胞谱系克隆产生,不要求恶性状态,保护肾功能需大幅降低单克隆蛋白。

研究设计与样本

  • 本文为综述,检索范围未报告。

主要发现

  • 肾小球损伤主要机制为沉积,包括Ig淀粉样变性、单克隆Ig沉积病、免疫触须样肾小球病和1/2型冷球蛋白血症性GN。
  • 非沉积机制包括补体系统激活导致C3肾小球病补体沉积、细胞因子/生长因子参与血栓性微血管病以及冷球蛋白血症中的沉淀。

关键数值与推荐

  • 不满足恶性肿瘤标准的肾毒性克隆称为具有肾脏意义的单克隆丙种球蛋白病。
  • 克隆导向策略如利妥昔单抗针对CD20表达B细胞、硼替佐米针对浆细胞克隆,较非单克隆蛋白相关肾病的免疫抑制方案更有效。

临床怎么用

  • 识别单克隆蛋白肾毒性,无论是否恶性,均需大幅降低单克隆蛋白以保护肾功能。
  • 可考虑克隆导向治疗如利妥昔单抗或硼替佐米。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Dysproteinemia is characterized by the overproduction of an Ig by clonal expansion of cells from the B cell lineage. The resultant monoclonal protein can be composed of the entire Ig or its components. Monoclonal proteins are increasingly recognized as a contributor to kidney disease. They can cause injury in all areas of the kidney, including the glomerular, tubular, and vascular compartments. In the glomerulus, the major mechanism of injury is deposition. Examples of this include Ig amyloidosis, monoclonal Ig deposition disease, immunotactoid glomerulopathy, and cryoglobulinemic GN specifically from types 1 and 2 cryoglobulins. Mechanisms that do not involve Ig deposition include the activation of the complement system, which causes complement deposition in C3 glomerulopathy, and cytokines/growth factors as seen in thrombotic microangiopathy and precipitation, which is involved with cryoglobulinemia. It is important to recognize that nephrotoxic monoclonal proteins can be produced by clones from any of the B cell lineages and that a malignant state is not required for the development of kidney disease. The nephrotoxic clones that do not meet requirement for a malignant condition are now called monoclonal gammopathy of renal significance. Whether it is a malignancy or monoclonal gammopathy of renal significance, preservation of renal function requires substantial reduction of the monoclonal protein. With better understanding of the pathogenesis, clone-directed strategies, such as rituximab against CD20 expressing B cell and bortezomib against plasma cell clones, have been used in the treatment of these diseases. These clone-directed therapies been found to be more effective than immunosuppressive regimens used in nonmonoclonal protein-related kidney diseases.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Leung N, Drosou ME, Nasr SH, et al. Dysproteinemias and Glomerular Disease. Clin J Am Soc Nephrol. 2017. PMID: 29114004. doi:10.2215/CJN.00560117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。